N-(4-氯-2-甲氧基苯基)乙酰胺 | 86412-57-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-氯-2-甲氧基苯基)乙酰胺
• 英文名称: 4'-chloro-o-acetanisidide
• 英文别名: N-(4-chloro-2-methoxyphenyl)acetamide
• CAS: 86412-57-9
• 化学式: C₉H₁₀ClNO₂
• 分子量: 199.637
• InChiKey: ZQRNYYMVIORHGW-UHFFFAOYSA-N

物化性质

• 沸点：
  334.2±27.0 °C(Predicted)
• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-氯-2-甲氧基苯基)乙酰胺 在 copper(I) bromide 、 氢氧化钾 、 potassium carbonate 作用下， 以 乙二醇 为溶剂， 反应 18.0h， 生成 4-chloro-N-(2-methoxyphenyl)-o-anisidine
  参考文献：
  名称：

  Fischer Indolization of Ethyl Pyruvate 2-Bis(2-methoxyphenyl)hydrazone and New Insight into the Mechanism of Fischer Indolization. (Fischer Indolization and Its Related Compounds. XXVII)

  摘要：

  为了研究取代的二苯肼在费歇尔吲哚化过程中的环化方向，我们对丙酮酸乙酯 2-双(2-甲氧基苯基)腙(6)进行了费歇尔吲哚化。结果表明，在二苯甲酮的费歇尔吲哚化过程中，环化并不总是向电子稠合核进行，而是取决于烯肼的构象。因此，费歇尔吲哚化应通过[3, 3]西格玛途径进行，并具有电子效应。

  DOI：

  10.1248/cpb.43.1287
• 作为产物：
  描述：

  2-硝基苯甲醚 在 盐酸 、 tin 作用下， 生成 N-(4-氯-2-甲氧基苯基)乙酰胺
  参考文献：
  名称：

  Herold, Chemische Berichte, 1882, vol. 15, p. 1685

  摘要：

  DOI：

文献信息

• HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS
  申请人：INTEGRAL BIOSCIENCES PRIVATE LIMITED

  公开号：US20200206233A1

  公开（公告）日：2020-07-02

  The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

  本公开涉及一般用于治疗与突变异柠檬酸脱氢酶（mt-IDH）相关的疾病的化合物，特别是突变IDH1酶。具体地，本发明揭示了式（IA）的化合物，该化合物对突变IDH1酶表现出抑制活性。还公开了使用该化合物治疗与突变IDH1酶过度活性相关的疾病的方法。此外，还公开了其用途、药物组合物和试剂盒。
• Fischer indolization and its related compounds. XXIV. Fischer indolization of ethyl pyruvate 2-(2-methoxyphenyl)phenylhydrazone.
  作者：Hisashi ISHI、Takao SUGIURA、Kimiko KOGUSURI、Toshiko WATANABE、Yasuoki MURAKAMI

  DOI：10.1248/cpb.39.572

  日期：——

  In order to clarify the mechanism of Fischer indolization of 2-methoxyphenylhydrazones, Fischer indolization of ethyl pyruvate 2-(2-methoxyphenyl)phenylhydrazone (2) was carried out with hydrochloric acid in ethanol and zinc chloride in acetic acid. The reactions proceeded smoothly to give N-arylindoles (11-14) and some chlorinated diphenylamine derivatives (8-10) as by-products. Consideration of the indole products revealed that the Fischer indolization proceeded mainly at the unsubstitued phenyl nucleus rather than at the 2-methoxyphenyl nucleus. This result is inconsistent with the previous result that Fischer indolization of diarylhydrazones proceeded at the electron-richer nucleus. The structures of the diphenylamines were determined by chemical means and the mechanism of their formation is discussed.

  为了阐明2-甲氧基苯基肼的Fischer吲哚化反应机理，用盐酸-乙醇和氯化锌-乙酸对乙基丙酮酸2-(2-甲氧基苯基)苯基肼(2)进行了Fischer吲哚化反应。反应顺利进行，生成N-芳基吲哚(11-14)和一些氯代二苯胺衍生物(8-10)作为副产物。对吲哚产物的分析表明，Fischer吲哚化主要发生在未取代的苯环上，而不是在2-甲氧基苯环上。这一结果与之前二芳基肼Fischer吲哚化反应发生在电子较富集的环上的结果不一致。通过化学方法确定了二苯胺的结构，并对其生成机理进行了讨论。
• Heterocyclic Kinase Inhibitors
  申请人：Hasvold A. Lisa

  公开号：US20070254867A1

  公开（公告）日：2007-11-01

  Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式的化合物对于抑制蛋白激酶很有用。还公开了制备这些化合物的方法、含有这些化合物的组合物和使用这些化合物的治疗方法。
• Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors
  申请人：Fujimoto Aki Roger

  公开号：US20070060569A1

  公开（公告）日：2007-03-15

  Compound of the formula wherein R represents OH or NHOH; R 1 represents hydrogen, optically substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid or from a sulfonic acid; R 2 represents biarylsulfonyl or aryloxyrylsulfonyl; R 3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or from a carbamic acid; R 4 and R 5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals.

  该公式的化合物中，R代表OH或NHOH; R1代表氢、光学取代的较低烷基、芳基-较低烷基、环烷基-较低烷基或由羧酸、碳酸、氨基甲酸或磺酸衍生的酰基; R2代表双芳基磺酰基或芳氧基芳基磺酰基; R3代表氢、可选取代的较低烷基、芳基-较低烷基、环烷基-较低烷基或由羧酸、碳酸或氨基甲酸衍生的酰基; R4和R5分别独立地代表氢、较低烷基、较低烷氧羰基、芳基-较低烷基或环烷基-较低烷基; m为零、1、2或3; 其药物可接受的前药衍生物; 其药物可接受的盐; 包括所述化合物的制药组合物; 以及它们用于抑制基质降解金属蛋白酶并预防或治疗哺乳动物基质金属蛋白酶依赖性疾病的用途。
• Copper‐Catalyzed Regioselective Halogenation of Anilides with <i>N</i> ‐Fluorobenzenesulfonimide
  作者：Lianwen Jin、Xiaoli Zeng、Siyang Li、Guofu Qiu、Peng Liu

  DOI：10.1002/ejoc.202200399

  日期：2022.6.27

  A copper-catalyzed direct chlorination and bromination of anilides with excellent regioselectivity and mono-substitution has been developed. This protocol provides an access to a broad range of arene chlorides and bromides from easily accessible arenes under mild conditions with cheap KCl or NaBr as the halogen source.

  已开发出具有优异区域选择性和单取代的铜催化苯胺直接氯化和溴化。该协议提供了在温和条件下使用廉价的 KCl 或 NaBr 作为卤素源从容易获得的芳烃中获得广泛的芳烃氯化物和溴化物的途径。